Phase 1 Chronic Kidney Disease Trial, Recruiting NCT04392206 Sponsor: Houssam Farres, M.D. Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 1 Chronic Kidney Disease Trial, Recruiting

NCT04392206
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 85 years old
  • Your doctor has planned for you to have an arteriovenous (AV) fistula created in your arm, and your anatomy is suitable for this procedure
  • You are able to communicate with the research team, can give written consent, and are willing and able to follow all study procedures
  • You are expected to live for at least 2 more years
  • If you are female, you must either be past menopause or unable to have children, which should be documented in your medical records, or you may need to take a pregnancy test

Who may not be able to join:

  • You have had cancer, or have been treated for cancer, in the last 6 months
  • You have a weakened immune system, including HIV/AIDS, or an active autoimmune disease
  • You have a condition that causes your blood to clot too easily, or you have had 2 or more blood clots (such as deep vein thrombosis) in the past
  • You have taken part in another research study involving an experimental drug or device in the last 60 days, or you have any other condition that the study doctor feels would affect the fairness of the results
  • You have had an organ transplant that did not work out and are currently taking anti-rejection medications
  • You currently have an active infection that is being treated

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Houssam Farres, MD, Mayo Clinic

Phone: (904) 953-2077

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Houssam Farres, M.D.
Registry
ClinicalTrials.gov
Start date
15 May 2020
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with treatment-related adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov